Palvella Therapeutics (PVLA) Current Assets (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Current Assets data on file, last reported at $263.2 million in Q1 2026.

• Current Assets for Q1 2026 came in at $263.2 million, up 231.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $263.2 million (up 231.36% YoY), and the FY2025 annual result was $59.0 million, down 33.15% from the prior year.
• Current Assets climbed to $263.2 million in Q1 2026 per PVLA's latest filing, from $59.0 million in the prior quarter.
• Over five years, Current Assets peaked at $263.2 million in Q1 2026 and troughed at $7.5 million in Q4 2023.
• A 5-year average of $84.2 million and a median of $73.6 million in 2022 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2024: Current Assets tumbled 89.72% in 2023, then surged 1068.97% in 2024.
• A 5-year view of Current Assets shows it stood at $73.4 million in 2022, then plunged by 89.72% to $7.5 million in 2023, then surged by 1068.97% to $88.2 million in 2024, then plunged by 33.15% to $59.0 million in 2025, then soared by 346.25% to $263.2 million in 2026.
• Business Quant data shows PVLA's Current Assets at $263.2 million in Q1 2026, $59.0 million in Q4 2025, and $66.9 million in Q3 2025.